Saturday 17 October 2026
Export IMRN’s income statement to Excel — free account
IMMURON
IMRN Healthcare Biotechnology
IMMURON’s revenue for fiscal 2026 (year ended June 2026) was $5.2 million, up 10.9% from fiscal 2025. Revenue growth for five consecutive years.
0.98
0.05
−4.85%
Follow IMRN
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
5.75 | 6.75 | 2.42 | 5.77 | |
Current Ratio |
7.17 | 8.04 | 5.10 | 6.80 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(2.22) | (1.68) | (3.97) | (2.60) | |
Working Capital |
7.48 | 8.58 | 5.21 | 6.53 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | — | |
Net Current Asset Value |
7.34 | 8.44 | 5.15 | 6.46 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
0.88 | 1.01 | 0.76 | 0.84 | |
Average Payables |
1.16 | 1.03 | 0.90 | 0.52 | |
Average Inventory |
1.29 | 1.26 | 0.86 | 0.66 | |
Average Assets |
9.51 | 11.45 | 10.68 | 11.56 | |
Average Common Equity |
7.90 | 10.00 | 9.22 | 10.36 |
Columns are period end dates · fundamentals updated 6 Oct 2026